Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02693535 · ClinicalTrials.gov registry record · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
A Phase 2 study of Multiple Myeloma and Advanced Solid Tumors, sponsored by American Society of Clinical Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 4,200
- Enrollment target
- 20
- Study locations
NCT02693535 is a Phase 2 study of Multiple Myeloma and Advanced Solid Tumors that is actively recruiting participants, run by American Society of Clinical Oncology. The registered enrollment target is 4,200 participants, above the 537-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (682% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT02693535, a Phase 2 study of Multiple Myeloma and Advanced Solid Tumors, is actively recruiting participants, sponsored by American Society of Clinical Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 4,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG Palbociclib
- DRUG Temsirolimus
- DRUG Trastuzumab and Pertuzumab
- DRUG Vemurafenib and Cobimetinib
Study Locations (20)
California
- Sutter Auburn - Auburn
- Sutter Alta Bates - Berkeley
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate - Los Angeles
- Kaiser Permanente - Oakland Medical Center - Oakland
- Sutter Palo Alto Medical Foundation: Palo Alto - Palo Alto
- Kaiser Permanente - Roseville Medical Center - Roseville
- Sutter Roseville - Roseville
- Kaiser Permanente - Sacramento Medical Center - Sacramento
- Sutter Sacramento - Sacramento
- Kaiser Permanente - South San Francisco Medical Center - San Francisco
- California Pacific Medical Center Research Institute - San Francisco
- Kaiser Permanente - San Francisco Medical Center - San Francisco
- Sutter Cancer Research Consortium - San Francisco
- Kaiser Permanente - San Jose Medical Center - San Jose
- Kaiser Permanente - San Leandro Medical Center - San Leandro
- Kaiser Permanente - Santa Clara Medical Center - Santa Clara
- Sutter Palo Alto Medical Foundation: Santa Cruz - Santa Cruz
- Sutter Palo Alto Medical Foundation: Fremont - Santa Cruz
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
Arizona
- Cancer Treatment Centers of America-Phoenix - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,200 participants |
| Start Date | 2016-03-14 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02693535
The ClinicalTrials.gov registry entry for NCT02693535 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 4,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 537-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (682% higher). The listed sponsor is American Society of Clinical Oncology, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Sunitinib is the first listed.
NCT02693535 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT02693535 about?
NCT02693535 is a clinical study titled "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer". The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include ...
What is the current status of trial NCT02693535?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 4,200 participants. The study started on 2016-03-14. Estimated completion is 2028-12-31.
What conditions does trial NCT02693535 study?
This clinical trial studies the following conditions: Multiple Myeloma, Advanced Solid Tumors, Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT02693535?
The interventions under investigation include: Sunitinib (DRUG), Palbociclib (DRUG), Temsirolimus (DRUG), Trastuzumab and Pertuzumab (DRUG), Vemurafenib and Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT02693535?
This trial is sponsored by American Society of Clinical Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02693535 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.